Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Real-World Study Assessing the Long-Term Outcomes from Contemporary Percutaneous Coronary Intervention with Newer Versus Traditional Dual Antiplatelet Regimes

Trial Profile

A Real-World Study Assessing the Long-Term Outcomes from Contemporary Percutaneous Coronary Intervention with Newer Versus Traditional Dual Antiplatelet Regimes

Completed
Phase of Trial: Phase IV

Latest Information Update: 19 Sep 2018

At a glance

  • Drugs Aspirin (Primary) ; Prasugrel (Primary) ; Ticagrelor (Primary) ; Clopidogrel
  • Indications Embolism; Stroke; Thrombosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Sep 2018 New trial record
    • 29 Aug 2018 Primary endpoint (MACCE (composite of death, MI, stroke, target vessel and lesion revascularization):Group B (Aspirin and Ticagrelor) versus Group A (Aspirin and Clopidogrel)) has been met, according to results presented at the ESC Congress 2018: Annual Congress of the European Society of Cardiology.
    • 29 Aug 2018 Results presented at the ESC Congress 2018: Annual Congress of the European Society of Cardiology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top